A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors.
Victor M SantanaNatasha SahrRuth G TatevossianSujuan JiaOlivia CampagneApril SykesClinton F StewartWayne L FurmanLisa M McGregorPublished in: Cancer (2020)
The maximum tolerated dose of cotreatment with bevacizumab and everolimus was 8 mg/kg of bevacizumab and 4 mg/m2 of everolimus in a 4-week cycle for children with recurrent solid tumors.